Genmab A/S Genmab To Present At Jefferies Virtual London Healthcare Conference
04 November 2021 - 1:18AM
UK Regulatory
TIDMGEN
Media Release
Copenhagen, Denmark, November 03, 2021
https://www.globenewswire.com/Tracker?data=hUFD_Hn-L2Un-5iu8HZtTB1ThF6XWRMYBCoMIvFF4OwcXu9AdxUs0uAJZ0ZbSIf1VlHx8x_1O1_7Ep7c-KmoDw==
Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de
Winkel, Ph.D., will take part in a fireside chat at the Jefferies
Virtual London Healthcare Conference on November 18, 2021. A
webcast of the event will be available on Genmab's website from
November 18, 2021, 9:00 AM CET at
https://ir.genmab.com/events-and-presentations#content.
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of people with cancer. For more than
20 years, Genmab's vision to transform cancer treatment has driven
its passionate, innovative and collaborative teams to invent
next-generation antibody technology platforms and leverage
translational research and data sciences, fueling multiple
differentiated cancer treatments that make an impact on people's
lives. To develop and deliver novel therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. Genmab's proprietary pipeline includes
bispecific T-cell engagers, next-generation immune checkpoint
modulators, effector function enhanced antibodies and antibody-drug
conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in
Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo,
Japan. For more information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=hUFD_Hn-L2Un-5iu8HZtTJuSxsXeoABkWP-a6ysstEqxdHvHTYXOy6VEJLUitDbOKKV_lgscZUPhx-pZYS_LozwZ_QWRmhDxFV-TpUOs8QwTVqCflb9KB81S8IsbR-yAE-RTTS2f7c5y21AR8Ste2Q==
and follow us on Twitter.com/Genmab
https://www.globenewswire.com/Tracker?data=sSe6pdxHQHaExc4vUCRlRyKb00U4kH3861hCb10F9SR11VsHGfK6R_GKMhqmFWkB7iDgLDJe-dVPhNvnUIl2hf_TgYLeXf4dOpIQ6WX9ugc=
.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations
& Communications
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=11oaTng47UfBiC3rySJRAZRb_sDruQPkQMTDQZey8GHN9ioaQkisKRfoezc93rzalxu-71Tm7nUa_EErWIrq9A==
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=csig2pOdNJHFk3i4OtnRrPo2HVGVWEAIGy7ji7WGlFr-wCCVr-CBquSYmRts5gar2EZJ4C2pPMPTmZvivCLzpQ==
This Media Release contains forward looking statements. The
words "believe", "expect", "anticipate", "intend" and "plan" and
similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=AZJQtfCf0bYuX3Ekn60CT7AS4XMcup2gLCBAb4MOTnaw6jN5SX42sNJu14oqKCbDYQwxC2Jo1dS9to4Lr9V5QQ==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=AZJQtfCf0bYuX3Ekn60CT4ldcUok9ioNrzk5hLpYnC5q_rsFA3HJ9_FkaX4zNHFhTANY2TcfzPIr56YFagCifAzPA_zGYoPhE5uK8o4ZfQw=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Media Release nor to
confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) ;
HexElect(R) ; and UniBody(R) .
Media Release no. 13
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 031121_i13_Jefferies
https://ml-eu.globenewswire.com/Resource/Download/9064cb4b-a42d-420b-8286-c217f588eca2
(END) Dow Jones Newswires
November 03, 2021 10:18 ET (14:18 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024